Skip to main content
. Author manuscript; available in PMC: 2014 Aug 18.
Published in final edited form as: J Alzheimers Dis. 2014;40(4):1005–1016. doi: 10.3233/JAD-131883

Figure 4.

Figure 4

Effects of OL-1 administered via tail vein 3 times at 2 week intervals on soluble (A–C), total (D–F), and the ratio of soluble/total (G–H) Aβ. Aβ levels were measured by ELISA, and analyzed by one-way ANOVA and Newman-Keuls multiple-comparisons test: **P<0.01, ***P<0.001 vs. RA Tg2576; ###P<0.001 vs. WT RA, n=6–8 per group.